Breast Cancer

bc-icon

In the United States, the estimated

number of new cases of BC for

2019 is ≈270,000.1

The 5-year survival rate

for metastatic BC is

27%.2

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend testing certain patients with mBC for biomarkers such as BRCA1/2 (germline), ER, PR, HER2, PIK3CA, and PD-L1.3

BRCA, breast cancer susceptibility gene; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer; NCCN, National Comprehensive Cancer Network; PD-L1, programmed death-ligand 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PR, progesterone receptor.

References: 1. Cancer Facts and Figures 2019. American Cancer Society; 2019. 2. Mariotto AB et al. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809-815. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V3.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed March 16, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.